MX2021009685A - Compuesto heterociclo pentaciclico. - Google Patents

Compuesto heterociclo pentaciclico.

Info

Publication number
MX2021009685A
MX2021009685A MX2021009685A MX2021009685A MX2021009685A MX 2021009685 A MX2021009685 A MX 2021009685A MX 2021009685 A MX2021009685 A MX 2021009685A MX 2021009685 A MX2021009685 A MX 2021009685A MX 2021009685 A MX2021009685 A MX 2021009685A
Authority
MX
Mexico
Prior art keywords
heterocyclic compound
pentacyclic heterocyclic
pentacyclic
xvii
formulae
Prior art date
Application number
MX2021009685A
Other languages
English (en)
Inventor
Yoshihiko Norimine
Koji Hagiwara
Nobuaki Sato
Nobuhiro Sato
Yu Yoshida
Yoshihisa Kobayashi
Yoshiaki Ohashi
Shinsuke Hirota
Tamaki HOSHIKAWA
Takaaki Harada
Hikaru YOSHIMURA
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2021009685A publication Critical patent/MX2021009685A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Este compuesto representado por cualquiera de las fórmulas (I) - (XVII) o una sal farmacéuticamente aceptable de este tiene un efecto colinérgico de activación neuronal y es aplicable como agente terapéutico para deterioro cognitivo. (ver Fórmulas).
MX2021009685A 2019-03-05 2020-03-03 Compuesto heterociclo pentaciclico. MX2021009685A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019039351 2019-03-05
PCT/JP2020/008881 WO2020179780A1 (ja) 2019-03-05 2020-03-03 五環式複素環化合物

Publications (1)

Publication Number Publication Date
MX2021009685A true MX2021009685A (es) 2021-09-10

Family

ID=72336168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009685A MX2021009685A (es) 2019-03-05 2020-03-03 Compuesto heterociclo pentaciclico.

Country Status (21)

Country Link
US (1) US11358972B2 (es)
EP (1) EP3936190A4 (es)
JP (1) JP7504864B2 (es)
KR (1) KR20210135224A (es)
CN (1) CN113453762B (es)
AR (1) AR118235A1 (es)
AU (1) AU2020232044A1 (es)
BR (1) BR112021015975A2 (es)
CA (1) CA3129861A1 (es)
CL (1) CL2021002144A1 (es)
CO (1) CO2021010512A2 (es)
EA (1) EA202191966A1 (es)
IL (1) IL285511B2 (es)
JO (1) JOP20210219A1 (es)
MA (1) MA55221A (es)
MX (1) MX2021009685A (es)
PE (1) PE20211978A1 (es)
SG (1) SG11202108780PA (es)
TW (1) TWI821537B (es)
WO (1) WO2020179780A1 (es)
ZA (1) ZA202105729B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020233452A1 (en) 2019-03-05 2021-09-02 Eisai R&D Management Co., Ltd. Salt of pentacyclic compound and crystals thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE258234C (es)
US4187306A (en) 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
RU2117670C1 (ru) 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (es) 1990-02-08 1993-01-01 Pfizer
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5736992A (en) * 1994-10-31 1998-04-07 Hewlett-Packard Pressure regulated free-ink ink-jet pen
KR100203456B1 (ko) * 1995-06-20 1999-06-15 한승수 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제
CL2004000348A1 (es) 1997-04-15 2005-01-14 Cephalon Inc & Kyowa Hakko Kog Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales.
CL2004000352A1 (es) 1998-05-26 2005-05-27 Cephalon Inc & Kyowa Hakko Kog Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales.
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
DE10246207B4 (de) * 2002-10-04 2008-04-03 Disetronic Licensing Ag Mikrodialysesonde mit spiralförmiger Leitung
US8252520B2 (en) 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
EP1807432A1 (en) 2004-10-20 2007-07-18 F. Hoffmann-Roche AG Halogen substituted benzodiazepine derivatives
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
GB201100181D0 (en) * 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2015174534A1 (ja) * 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
JOP20200030A1 (ar) 2017-09-07 2020-02-12 Eisai R&D Man Co Ltd مركب خماسي الحلقة
AU2020233452A1 (en) 2019-03-05 2021-09-02 Eisai R&D Management Co., Ltd. Salt of pentacyclic compound and crystals thereof

Also Published As

Publication number Publication date
CA3129861A1 (en) 2020-09-10
JP7504864B2 (ja) 2024-06-24
CO2021010512A2 (es) 2021-10-29
US20200283452A1 (en) 2020-09-10
ZA202105729B (en) 2022-08-31
US11358972B2 (en) 2022-06-14
PE20211978A1 (es) 2021-10-05
JPWO2020179780A1 (es) 2020-09-10
EP3936190A4 (en) 2022-11-16
TW202100528A (zh) 2021-01-01
CN113453762A (zh) 2021-09-28
EA202191966A1 (ru) 2021-12-08
CN113453762B (zh) 2024-06-07
AU2020232044A1 (en) 2021-09-02
KR20210135224A (ko) 2021-11-12
IL285511B2 (en) 2024-10-01
EP3936190A1 (en) 2022-01-12
SG11202108780PA (en) 2021-09-29
BR112021015975A2 (pt) 2021-10-05
AR118235A1 (es) 2021-09-22
IL285511A (en) 2021-09-30
JOP20210219A1 (ar) 2023-01-30
IL285511B1 (en) 2024-06-01
MA55221A (fr) 2022-01-12
CL2021002144A1 (es) 2022-02-04
TWI821537B (zh) 2023-11-11
WO2020179780A1 (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
MX2020011250A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
AU2017264697A1 (en) Combination treatment of ocular inflammatory disorders and diseases
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MY196172A (en) Tricyclic Spiro Compound
PH12019501074A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2021006695A (es) Moduladores de trex1.
PH12017500513A1 (en) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2021007247A (es) Derivados de rapamicina.
PH12018502378A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
PH12017501652B1 (en) Kv1.3 inhibitors and their medical application
MX2019005934A (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).
PH12021550713A1 (en) Medicament for the treatment of chronic cough
WO2018125961A8 (en) Poly-adp ribose polymerase (parp) inhibitors
PH12016502246A1 (en) Carboxamide derivatives
PH12020551772A1 (en) Oxo-substituted compound
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2021009685A (es) Compuesto heterociclo pentaciclico.
MX2009003728A (es) Nuevos derivados de alcaloides de isocarbostirilo que tienen actividades anti-proliferativas y anti-migratorias.
WO2023211684A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
MX2021014458A (es) Compuestos triciclicos.
WO2018005444A3 (en) Methods for treating cancer
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical